Pharmasset Inc. (fka VRUS)

[oc631]

Just a correction to MSN Moneycentral's company description of Pharmasset which is listed on the top of the IHUB VRUS homepage.

Clevudine, an oral pyrimidine nucleoside analog, for the treatment of HBV, which is entering the United States and European Phase III registration clinical trials, and is approved for HBV in South Korea and marketed by Bukwang Pharm. Co., Ltd. under the brand name Levovir;

Clevudine entered the biotech graveyard many years ago. No longer in the pipeline. PSI-7977, PSI-938, and PSI-661 aren't mentioned either indicating their description is quite outdated.